Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)

Contraception Clinical Trial

Official title:

A Randomized, Open-Label, Comparative Trial to Evaluate the Effects on Ovarian Function of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2), Compared to a Monophasic COC Containing 3 mg Drospirenone (DRSP) and 30 ug Ethinyl Estradiol (EE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00511433
• Other study ID #: P05723
• Secondary ID: Organon protocol
• Status: Completed
• Phase: Phase 3
• Start date: October 2006
• Est. completion date: January 2008

Study information

• Verified date: February 2022
• Source: Organon and Co
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to evaluate the effects of the nomegestrol acetate-estradiol (NOMAC-E2) combined oral contraceptive (COC) on ovarian function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: January 2008
• Est. primary completion date: January 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Willing to use COC for at least 6 cycles.

• 18 - 35 years of age at screening.

• Body Mass Index (BMI) of >/= 17 and </= 35.

• Good physical and mental health.

• Willing to use condoms as the sole contraceptive method during screening cycle and 1 post-treatment cycle.

• Willing to give informed consent.

Exclusion Criteria:

• Contraindications for contraceptive steroids (general).

• Additional contraindications (renal, hepatic or adrenal insufficiency).

• Breastfeeding.

• Present use (or use within 2 months prior to start of the trial medication) of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex

steroids (other than pre- and post treatment contraceptive method) and herbal remedies containing Hypericum perforatum (St. John's Wort).

• Administration of any other investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.

• Abnormal cervical smear at screening, or documentation of an abnormal smear performed within 6 months before screening.

• Clinically relevant abnormal laboratory result at screening as judged by the investigator.

Related Conditions & MeSH terms

• Contraception

Intervention

Drug:
• NOMAC-E2
Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
• DRSP-EE
Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Organon and Co

References & Publications (1)

Duijkers IJ, Klipping C, Grob P, Korver T. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect on Ovarian Function as Determined by the Number of Participants With an Occurrence of Ovulation	During treatment, ovulation was assessed for each participant by the investigator on the basis of ultrasound scanning (USS). The final analysis was based on assessor-blind adjudication.	Cycle 1, Cycle 2, and Cycle 6
Primary	Effect on Ovarian Function as Determined by the Maximum Follicle Diameter	The maximum follicular diameter was defined as the largest follicular diameter during a treatment cycle.	Screening cycle, Cycle 1, Cycle 2, Cycle 3, and Cycle 6
Primary	Effect on Ovarian Function as Determined by the Maximum Progesterone Value	The maximum progesterone value was defined as the largest value during a cycle.	Screening cycle, Cycle 1, Cycle 2, Cycle 3, and Cycle 6
Primary	Effect on Ovarian Function as Determined by 17 Beta-estradiol (E2)	The parameter was measured at pre-defined study days.	Cycle 1, Cycle 2, Cycle 3, and Cycle 6
Primary	Effect on Ovarian Function as Determined by Follicle Stimulating Hormone (FSH)	The parameter was measured at pre-defined study days.	Cycle 1, Cycle 2, Cycle 3, and Cycle 6
Primary	Effect on Ovarian Function as Determined by Luteinizing Hormone (LH)	The parameter was measured at pre-defined study days.	Cycle 1, Cycle 2, Cycle 3, and Cycle 6
Secondary	Effect on Cervical Mucus as Determined by Insler Score	The Insler Score was assessed on Day 6 after ovulation during the Screening Cycle, on Day 21 of Cycle 1, and when the maximum follicle diameter was greater than or equal to 15 mm. The Insler Score consisted of four categories each scaled from 0 (none) to 3 (complete). The higher the score, the greater the cervical reaction.	Screening Cycle, Cycle 1, Cycle 2, and Cycle 7 (post-treatment cycle)
Secondary	Effect on Maximum Endometrial Thickness	Maximum endometrial thickness was defined as the largest endometrial thickness during a cycle.	Screening Cycle, Cycle 1, Cycle 2, and Cycle 6
Secondary	Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)	In-treatment pregnancies were pregnancies with an estimated date of conception from the day of first intake of trial medication up to and including the day of last (active or placebo) intake of trial medication extended with a maximum of two days. Each 13 cycles (28 days per cycle) of exposure constitutes a woman year. The Pearl Index was obtained by dividing the number of in-treatment pregnancies that occurred by the time (in 100 woman years) that the women were under risk of becoming pregnant.	6 cycles
Secondary	Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the "expected non-bleeding period" that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle.	Every 28-day cycle for 6 cycles
Secondary	Number of Participants With an Occurrence of Absence of Withdrawal Bleeding	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Absence of withdrawal bleeding was defined as no bleeding/spotting episode that began during or continued into the "expected bleeding period". Expected bleeding period: DRSP-EE group: 7-day period starting on Day 22 of the cycle; NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle.	Every 28-day cycle for 6 cycles
Secondary	Number of Participants With an Occurrence of Breakthrough Bleeding	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding was defined as any bleeding episode that occurred during the "expected non-bleeding period" that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2:21-day period starting on Day 4 of the cycle.	Every 28-day cycle for 6 cycles
Secondary	Number of Participants With an Occurrence of Breakthrough Spotting (Spotting Only)	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough spotting was defined as any spotting episode that occurred during the "expected non-bleeding period" that was neither part of an early nor continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2:21-day period starting on Day 4 of the cycle.	Every 28-day cycle for 6 cycles
Secondary	Number of Participants With an Occurrence of Early Withdrawal Bleeding	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Early withdrawal bleeding was defined as any withdrawal bleeding that started before the current "expected bleeding period". Expected bleeding period: DRSP-EE: 7-day period starting on Day 22 of the cycle; NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle.	Every 28-day cycle for 6 cycles
Secondary	Number of Participants With an Occurrence of Continued Withdrawal Bleeding	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Continued withdrawal bleeding was defined as any withdrawal bleeding that continued into the "expected non-bleeding period" of the next cycle. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle.	Every 28-day cycle for 5 cycles
Secondary	Average Number of Breakthrough Bleeding/Spotting Days	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Breakthrough bleeding/spotting was defined as any episode that occurred during the "expected non-bleeding period" that was neither an early nor a continued withdrawal bleeding. Expected non-bleeding period: DRSP-EE group: 21-day period starting on Day 1 of the cycle; NOMAC-E2: 21-day period starting on Day 4 of the cycle.	Every 28-day cycle for 6 cycles
Secondary	Average Number of Withdrawal Bleeding Days	Cycle control was evaluated on the basis of vaginal bleeding pattern as recorded daily by participants using diary card booklets. Participants documented whether vaginal bleeding was present, and if present, indicated whether it was considered to be spotting or bleeding. Withdrawal bleeding was defined as bleeding/spotting episode that started during or continued into the "expected bleeding period". Expected bleeding period: DRSP-EE group: 7-day period starting on Day 22 of the cycle; NOMAC-E2: 7-day period starting on Day 25 of the cycle and ending on Day 3 of the next cycle.	Every 28-day cycle for 6 cycles